ReviewHepatobiliary surgery and nutrition2018
New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fatty liver disease.
Review in Hepatobiliary surgery and nutrition, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 24 citations in OpenAlex.
- Patatin-like phospholipase domain-containing 3 (PNPLA3) variants rs 738408 and rs 738409 single nucleotide polymorphism as predictor of metabolic associated fatty liver disease and its progression.Pakistan journal of medical sciences · 2025Article
- Combined effects of genetic background and diet on mouse metabolism and gene expression.iScience · 2024Article
- Nonalcoholic liver disease: Epidemiology, risk factors, natural history, and management strategies.Annals of the New York Academy of Sciences · 2023Review
- Epigenetics as a versatile regulator of fibrosis.Journal of translational medicine · 2023Review
- Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm.International journal of molecular sciences · 2022Review
- Influences of Vitamin D Levels and Vitamin D-Binding Protein Polymorphisms on Nonalcoholic Fatty Liver Disease Risk in a Chinese Population.Annals of nutrition & metabolism · 2022Article
- Nonalcoholic steatohepatitis: global impact and clinical consequences.Endocrine connections · 2021Review
- Gene-Environmental Interactions as Metabolic Drivers of Nonalcoholic Steatohepatitis.Frontiers in endocrinology · 2021Review
- Oxidative Stress in NAFLD: Role of Nutrients and Food Contaminants.Biomolecules · 2020Review
- Review
- The metabolic basis of nonalcoholic steatohepatitis.Endocrinology, diabetes & metabolism · 2020Review
- Non-alcoholic fatty liver disease (NAFLD) diagnosis and management-differentiating the essential from the ancillary and the present from the future.Hepatobiliary surgery and nutrition · 2020Article
- PNPLA3 and nonalcoholic fatty liver disease: towards personalized medicine for fatty liver.Hepatobiliary surgery and nutrition · 2020Article
- Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis.Cell metabolism · 2020Article
- New Perspectives on Genetic Prediction for Pediatric Metabolic Associated Fatty Liver Disease.Frontiers in pediatrics · 2020Review
- The dawn of a new era for nonalcoholic fatty liver disease?Hepatobiliary surgery and nutrition · 2019Article
- Shared and distinct mechanisms of fibrosis.Nature reviews. Rheumatology · 2019Review
- Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment.Gene expression · 2019Review
- Modeling Steatohepatitis in Humans with Pluripotent Stem Cell-Derived Organoids.Cell metabolism · 2019Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the most common form of chronic liver disease in the United States affecting 80-100 million Americans. NAFLD encompasses a spectrum of diseases ranging from excess liver fat (nonalcoholic fatty liver or NAFL), to necro-inflammation (nonalcoholic steatohepatitis or NASH), to fibrosis/ cirrhosis, and malignant transformation (hepatocellular carcinoma). Susceptibility to NAFLD is highly variable and it remains unclear why some patients with NAFLD exhibit NASH, whereas patients with known risk factors have NAFL only. The reasons for this variability can be a partially attributed to differences in genetic background. In the last decade, there have been multiple genome wide association studies, which have enriched our understanding of the genetic basis of NAFLD. The
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.